APA (7th ed.) Citation

SALAVAT, M. P., ȘECLĂMAN, E. P., MUȘAT, A., BORUGĂ, M., PATONI, C., POPESCU, M., . . . PATONI, S. I. P. (2023). Aflibercept Versus Bevacizumab as First-Line Therapy in Age-Related Macular Degeneration. Current Health Sciences Journal, 49(4), 503. https://doi.org/10.12865/CHSJ.49.03.04

Chicago Style (17th ed.) Citation

SALAVAT, MĂDĂLINA-CASIANA PALFI, EDWARD PAUL ȘECLĂMAN, ANDREEA-ALEXANDRA MUȘAT, MĂDĂLINA BORUGĂ, CRISTINA PATONI, MARIUS-NICOLAE POPESCU, OANA ELENA TEODORESCU, OVIDIU MUȘAT, and STELLA IOANA POPESCU PATONI. "Aflibercept Versus Bevacizumab as First-Line Therapy in Age-Related Macular Degeneration." Current Health Sciences Journal 49, no. 4 (2023): 503. https://doi.org/10.12865/CHSJ.49.03.04.

MLA (9th ed.) Citation

SALAVAT, MĂDĂLINA-CASIANA PALFI, et al. "Aflibercept Versus Bevacizumab as First-Line Therapy in Age-Related Macular Degeneration." Current Health Sciences Journal, vol. 49, no. 4, 2023, p. 503, https://doi.org/10.12865/CHSJ.49.03.04.